Preview

Тазовая хирургия и онкология

Расширенный поиск

Трифлуридин / типирацил (FTD / TPi, TAs-102) в лечении больных метастатическим раком толстой кишки: от предклинических экспериментов до рутинной практики

https://doi.org/10.17650/2686-9594-2020-10-3-4-11-26

Полный текст:

Аннотация

Появление новых опций терапии с каждым годом приближает метастатический рак толстой кишки к понятию действительно хронического заболевания, которое может протекать годами. Одной из таких опций является новый химиопрепарат трифлуридин / типирацил (FTD / TPI, TAS-102), уже зарегистрированный более чем в 60 странах. Он позволяет увеличить продолжительность жизни пациентов при приемлемом уровне нежелательных явлений, чей спектр в основном представлен гематологическими осложнениями. В настоящем обзоре литературы будут рассмотрены все аспекты, связанные с данным препаратом, – от изучения фармакокинетики и определения максимально переносимой дозы, возможности применения при нарушениях функции печени до результатов комбинации препарата с таргетной терапией и сравнения с другими лечебными подходами у химиорефрактерных больных метастатическим раком толстой кишки.

Об авторе

М. Ю. Федянин
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России; ФГАОУ ВО «Российский университет дружбы народов»; ГБУЗ г. Москвы «Городская клиническая больница № 40 Департамента здравоохранения г. Москвы»
Россия

115478 Москва, Каширское шоссе, 24; кафедра онкологии и гематологии факультета непрерывного медицинского образования, 117198 Москва, ул. Миклухо-Маклая, 21, корп. 3; 129301 Москва, пос. Коммунарка, ул. Сосенский стан, 8



Список литературы

1. Chiang C.L., Choi H.C., Lam K.O. et al. Real-world treatment patterns and outcomes in refractory metastatic colorectal cancer. Asia-Pac J Clin Oncol 2019;1–9.

2. Emura T., Suzuki N., Fujioka A. et al. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the coadministration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. Int J Oncol 2005;27:449–55.

3. Dexter D.L., Wolberg W.H., Ansfield F.J. et al. The clinical pharmacology of 5-trifluoromethyl-20-deoxyuridine. Cancer Res 1972;32:247–53.

4. Fukushima M., Suzuki N., Emura T. et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 20-deoxyribonucleosides. Biochem Pharmacol 2000;59:1227–36.

5. Salonga D., Danenberg K.D., Johnson M. et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322–7.

6. Ansfield F.J., Ramirez G. Phase I and II studies of 20-deoxy-5-(trifluoromethyl)- uridine (NSC-75520). Cancer Chemother Rep 1971;55:205–8.

7. Tanaka N., Sakamoto K., Okabe H. et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 2014;32:2319–26.

8. Temmink O.H., Comijn E.M., Fukushi ma M., Peters G.J. Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. Nucleosides Nucleotides Nucleic Acids 2004;23:1491–4.

9. Santi D.V., Sakai T.T. Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-20-deoxyuridylic acid. Biochemistry 1971;10:3598–607.

10. Eckstein J.W., Foster P.G., Finer-Moore J. et al. Mechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)-20-deoxyuridine 50-monophosphate. Biochemistry 1994;33:15086–94.

11. Reyes P., Heidelberger C. Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: its mechanism of action and inhibition by fluorinated nucleotides. Mol Pharmacol 1965;1:14–30.

12. Oguchi K., Sakamoto K., Kazuno H. et al. TAS-102 treatment results in high trifluridine incorporation into DNA with pyrimidine metabolic pathway markedly up-regulated in cancer. Eur J Cancer 2014;50(Suppl 6):abstr.27.

13. Suzuki N., Emura T., Fukushima M. Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes. Int J Oncol 2011;39:263–70.

14. Matsuoka K., Iimori M., Niimi S. et al. Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks. Mol Cancer Ther 2015;14:1004–13. DOI: 10.1158/1535-7163.MCT-14-0236.

15. Emura T., Nakagawa F., Fujioka A. et al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 2004;13:249–55.

16. Matsuoka K., Kobunai T., Takechi T. Efficacy of trifluridine for 5-fluorouracilresistant human gastric cancer cell lines and their mechanisms. Cancer Res 2014;74(Suppl 19):abstr.781.

17. Bijnsdorp I.V., Peters G.J., Temmink O.H. et al. Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer 2010;126:2457–68.

18. Matsushita S., Nitanda T., Furukawa T. et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res 1999;59:1911–6.

19. Takao S., Akiyama S.I., Nakajo A. et al. Suppression of metastasis by thymidine phosphorylase inhibitor. Cancer Res 2000;60:5345–8.

20. Heidelberger C., Dexter D.L., Wolberg W.H. Clinical pharmacology of 5-triflu oromethyl-2’-deoxyuridine (F3TDR). Proc Am Assoc Cancer Res 1970:35.

21. Yagoda A., Helson L., Krakoff I.H. et al. Phase I trials of F3TDR (trifluoromethyl-2’-deoxyuridine). 10 th Int Cancer Congress, Houston 1970;793:490–1.

22. Hong D.S., Abbruzzese J.L., Bogaard K. et al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 2006;107:1383–90.

23. Dwivedy S., Hoff P.M., Dumas P. et al. Safety and pharmacokinetics (PK) of an antitumor/antiangiogenic agent, TAS-102: a phase I study for patients (PTS) with solid tumors. J Clin Oncol 2001;20:abstr.386.

24. Thomas M.B., Hoff P.M., Carter S. et al. A dose-finding, safety and pharmacokinetics study of TAS-102, an antitumor/ antiangiogenic agent given orally on a oncedaily schedule for five days every three weeks in patients with solid tumors. Proc Am Assoc Cancer Res 2002;43:abstr.2754.

25. Overman M.J., Varadhachary G., Kopetz S. et al. Phase 1 study of TAS-102 administered once daily on a 5-day-per week schedule in patients with solid tumors. Invest New Drugs 2008;26:445–54. DOI: 10.1007/s10637-008-9142-3.

26. Overman M.J., Kopetz S., Varadhachary G. et al. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 2008;26:794–9.

27. Green M.C., Pusztai L., Theriault L.R. et al. Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2006;24:abstr.10576.

28. Dоi T., Ohtsu A., Yoshino T. et al. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 2012;107:429–34.

29. Patel M.R., Bendell J.C., Mayer R.J. et al. A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol 2012;30(Suppl):abstr.3631.

30. Bendell J.C., Rosen L.S., Mayer R.J. et al. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol 2015;76(5):925–32.

31. Yoshino T., Mizunuma N., Yamazaki K. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2012;13:993–1001.

32. Becerra C.R., Yoshida K., Mizuguchi H. et al. A phase 1, open-label, randomized, crossover study evaluating the bioavailability of TAS-102 (trifluridine/tipiracil) tablets relative to an oral solution containing equivalent amounts of trifluridine and tipiracil. J Clin Pharmacol 2017;57(6):751–9.

33. Wang X., Zhou J., Li Y. et al. Pharmacokinetics, safety, and preliminary efficacy of oral trifluridine/tipiracil in Chinese patients with solid tumors: a phase 1b, open-label study. Clin Pharmacol 2020;12:21–33.

34. Saif M.W., Rosen L., Rudek M.A. et al. Open-label study to evaluate trifluridine/ tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. Br J Clin Pharmacol 2019;85(6):1239–46.

35. Mayer R., Van Cutsem E., Falcone A. et al. Randomized trial of TAS-102 refractory metastatic colorectal cancer. N Engl J Med 2015;372:1909–19.

36. Mayer R.J., Ohtsu A., Yoshino T. et al. TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: final survival results of the phase III recourse trial. J Clin Oncol 2016;34(4 Suppl):634.

37. Van Cutsem E., Mayer R.J., Laurent S. et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer 2018;90:63–72.

38. Van Cutsem E., Ohtsu A., Busto N.L. et al. Time to grade ≥3 adverse events in pts receiving trifluridine/tipiracil (TAS-102). J Clin Oncol 2017;35(Suppl 4S):abstr.788.

39. Van Cutsem E., Falcone A., Garcia-Carbonero R. et al. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. ESMO Open 2017;2(5):e000261.

40. Tabernero J., Van Cutsem E., Ohtsu A. et al. QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer. ESMO Open 2017;2(5):e000284.

41. Falcone A., Taieb J., Price T.J. et al. Quality of life at baseline in the international open-label early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb). J Clin Oncol 2018;36(4 Suppl):803.

42. Taieb J., Timothy J.P., Ciardiello F. et al. Health-related quality of life in the early-access phase IIIb study of trifluridine/ tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study. J Clin Oncol 2019;37(Suppl 4):abstr.638.

43. Xu J., Kim T.W., Shen L. et al. Results of a randomized, double-blind, placebo controlled, phase III trial of trifluridine/ tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol 2018;36(4):350–8.

44. Iveson T., Carter A.M., Shiu K.K. et al. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. BMC Cancer 2020;20(1):91.

45. Mayer R.J., Hochster H.S., Cohen S.J. et al. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2018;82:961–9.

46. Kasper S., Kisro J., Fuchs M. et al. Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer. BMC Cancer 2018;18(1):1124.

47. Samawi H.H., Brezden-Masley C., Afza A.R. et al. Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada. Curr Oncol 2019;26(5):319–29.

48. Kimura M., Usami E., Teramachi H. et al. Evaluation of tolerability of trifluridine/ tipiracil combination tablet in patients with advanced/recurrent colorectal cancer. Anticancer Res 2019;39(2):1029–34.

49. Yasue F., Kimura M., Usami E. et al. Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. Pharmazie 2018;73:178–81.

50. Kwakman J.J.M., Vink G., Vestjens J.H. et al. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. Int J Clin Oncol 2018;23(3):482–9.

51. Cremolini C., Rossini D., Martinelli E. et al. Trifluridine/tipiracil (TAS-102) in refractory metastatic colorectal cancer: a multicenter register in the frame of the Italian Compassionate Use Program. Oncologist 2018;23:1178–87.

52. Garcia-Alfonso P., Ruiz A., Carrato A. et al. Compassionate use program with FDT-TPI (trifluridine-tipiracil) in pre-treated metastatic colorectal cancer patients: Spanish real world data. J Clin Oncol 2017;35(Suppl):e15019.

53. Salvatore L., Niger M., Bellu E. et al. Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overview. Ann Oncol 2016;27:149–206.

54. Montes A.F., Rivera F.V., Lago N.M. et al. Efficacy and safety of trifluridine/ tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. Clin Transl Oncol 2020;22:351–9.

55. Carriles C., Jimenez-Fonseca P., Sánchez-Cánovas M. et al. Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status. Clin Transl Oncol 2019;21(12):1781–5.

56. Unseld M., Drimmel M., Siebenhüner A. et al. Optimizing treatment sequence for late-line metastatic colorectal cancer patients using trifluridine/tipiracil and regorafenib. Clin Colorectal Cancer 2018;17(4):274–9.

57. Sforza V., Martinelli E., Cardone C. et al. Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open 2017;2(4):e000229.

58. Masuishi T., Taniguchi H., Hamauchi S. et al. Regorafenib versus trifluridine/ tipiracil for refractory metastatic colorectal cancer: a retrospective comparison. Clin Colorectal Cancer 2017;16(2):e15–e22.

59. Kotani D., Shitara K., Kawazoe A. et al. Safety and efficacy of trifluridine/tipiracil monotherapy in clinical practice for patients with metastatic colorectal cancer: experience at a single institution. Clin Colorectal Cancer 2016;15(3):e109–15.

60. Moriwaki T., Fukuoka S., Taniguchi H. et al. Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese society for cancer of the colon and rectum multicenter observational study. Oncologist 2018;23:7–15.

61. Arita S., Shirakawa T., Matsushita Y. et al. Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer. Anticancer Res 2016;36:1959–66.

62. O’Brien C., Callaghan S., Papaxoinis G. et al. TAS 102 in refractory metastatic colorectal cancer: UK expanded access programme experience. J Clin Oncol 2017;35(Suppl):e15043.

63. Coutzac C., Trouilloud I., Artru P. et al. Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective “real life” study. J Clin Oncol 2020;38(Suppl): abstr.4036.

64. Stavraka C., Pouptsis A., Synowiec A. et al. Trifluridine/tipiracil in metastatic colorectal cancer: an updated multicentre real-world analysis on efficacy, safety and predictive factors. Ann Oncol 2019;30(Suppl 5):v198–v252.

65. Patel A.K., Ng K., Duh M.S. et al. Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A single institution retrospective study. J Clin Oncol 2019;37(Suppl 4):abstr.592.

66. Grell P., Dvorak J., Vocka M. et al. Prediction of trifluridine/tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer (mCRC): Real-life data from the Czech Republic. J Clin Oncol 2019;37(Suppl):abstr.e15102.

67. Kawakami T., Yamazak K., Oki E. et al. Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study. Ann Oncol 2018;29(Suppl 8):viii150–204.

68. Falcone A., Andre T., Edeline J. et al. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase 3b, international open-label, early-access study. Ann Oncol 2018;29(5):v104–53.

69. Lopez C.A., Azimi-Nekoo E., Chung S.Y. et al. Meta-analysis and systematic review of the cardiotoxicity of TAS-102. J Clin Oncol 2020;38(Suppl):abstr.e16053.

70. Tsukihara H., Nakagawa F., Sakamoto K. et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep 2015;33:2135–42.

71. Kuboki Y., Nishina T., Shinozaki E. et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicenter, phase 1/2 study. Lancet Oncol 2017;18:1172–81.

72. Kotani D., Kuboki Y., Horasawa S. et al. Retrospective cohort study of trifluridine/ tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer 2019;19(1):1253.

73. Kagawa Y., Nose Y., Hata T. et al. Safety and efficacy of trifluridine/tipiracil (FTD/TPI) plus bevacizumab in clinical practice for patients with chemorefractory metastatic colorectal cancer: A retro spective comparative study. J Clin Oncol 2020;38(Suppl 4):abstr.112.

74. Nakamura M., Satake H., Oba K. et al. Final results of multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with mCRC refractory to standard therapies (BiTS study). J Clin Oncol 2020;38(Suppl 4):abstr.121.

75. Kazama K., Nakamura M., Tanaka R. et al. JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies. Ann Oncol 2019;30(Suppl 5):v198–v252.

76. Oki T.E., Makiyama A., Miyamoto Y. et al. Rifluridine/tipiracil plus bevacizumab in elderly patients with previously untreated metastatic colorectal cancer (KSCC1602): A multicenter, phase II clinical trial. J Clin Oncol 2019;37(Suppl):abstr.3548.

77. Pfeiffer P., Yilmaz M., Möller S. et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21(3):412–20.

78. Lesniewski-Kmak K., Moiseenko V., Saunders M. et al. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis. Ann Oncol 2018;29:mdy149.021.

79. Moiseyenko V., Saunders M.P., Wasan H.S. et al. QoL from TASCO1: Health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy — Results from the TASCO1 phase II study. J Clin Oncol 2019;37(Suppl 4):676.

80. André T., Saunders M., Kanehisa A. et al. First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. Future Oncol 2020;16(4):21–9.

81. Baba Y., Tamura T., Satoh Y. et al. Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine. Mol Oncol 2017;11(8):1065–77.

82. Kuboki Y., Yoshino T., Kato T. et al. APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC). J Clin Oncol 2018;36(15 Suppl):3523.

83. Townsley C.A., Major P., Siu L.L. et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006;94(8):1136–43.

84. Moehler M.H., Stein A., Trojan J. et al. Regorafenib with TAS-102 (REGOTAS) in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY). J Clin Oncol 2020;38(Suppl 4):abstr.158.

85. Suzuki N., Nakagawa F., Matsuoka K, Takechi T. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts. Oncol Rep 2016;36(6):3123–30.

86. Nishina T., Kuboki Y., Shinozaki E. et al. A multicentre phase I/II study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-TASK FORCE: EPOC1410); Phase I results. Ann Oncol 2016;27(Suppl 6):P472.

87. Temmink O.H., Hoebe E.K., Van Der Born K. et al. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 2016;96(2):231–40.

88. Argilés G., André T., Hollebecque A. et al. Phase I dose-escalation of Trifluridine/ Tipiracil in combination with Oxaliplatin in patients with metastatic colorectal cancer. Eur J Cancer 2019;112:12–9.

89. Temmink O.H., Hoebe E.K., Fukushima M., Peters G.J. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur J Cancer 2007;43(1):175–83.

90. Nukatsuka M., Nakagawa F., Saito H. et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res 2015;35(3):1437–45.

91. Dоi T., Yoshino T., Fuse N. et al. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Invest New Drugs 2015;33(5):1068–77.

92. Varghese A.M., Cardin D.B., Hersch J. et al. Phase I study of Trifluridine/Tipiracil plus Irinotecan and Bevacizumab in advanced gastrointestinal tumors. Clin Cancer Res 2020;26(7):clincanres. 2743.2019.

93. Bijnsdorp I.V., Kruyt F.A., Gokoel S. et al. Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. Cancer Sci 2008;99(11):2302–8.

94. Fidelman N., Atreya C.E., Griffith M.J. et al. Phase I prospective trial of TAS-102 (trifluride and tipiracil) and radioembolization with 90 Y resin microspheres for chemo-refractory colorectal liver metastases. J Clin Oncol 2020;38(Suppl 4):abstr.110.

95. Hubbard J.M., Leal A.D., Hallemeier C.L. et al. Phase I trial of TAS-102 and concurrent radiation therapy for patients with locally recurrent, unresectable or metastatic, rectal cancer. J Clin Oncol 2018;36(Suppl):abstr.TPS3623.

96. Suzuki N., Tsukihara H., Nakagawa F. et al. Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells. Am J Cancer Res 2017;7(10):2032–40.

97. Limagne E., Nuttin L., Spill A. et al. P-256 trifluridine/tipiracil combined to oxaliplatin sensitizes microsatellite stable colorectal cancer to anti-PD-1 blockade. Ann Oncol 2017;28(Suppl 3): mdx261.254.

98. Patel M.R., Falchook G.S., Hamada K. et al. Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). J Clin Oncol 2019;37(Suppl 8):abstr.48.

99. Bordonaro R., Calvo A., Auriemma A. et al. Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab: Results of the expansion part of a phase I study in patients with metastatic colorectal cancer. J Clin Oncol 2020;38(Suppl 4):abstr.140.

100. Kimura M., Usami E., Iwai M. et al. Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy. Pharmazie 2017;72:49–52.

101. Hamauchi S., Yamazaki K., Masuishi T. et al. Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102. Clin Colorectal Cancer 2017;16:51–7.

102. Ohtsu A., Yoshino T., Falcone A. et al. Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/ Tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer. J Clin Oncol 2017;34:775.

103. Tabernero J., Sobrero A.F., Borg C. et al. Exploratory analysis of the effect of FTD/ TPI in patients treated in RECOURSE by prognostic factors. J Clin Oncol 2019;37(Suppl 4):abstr.677.

104. Tanaka A., Sadahiro S., Suzuki T. et al. Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer. Oncol Lett 2018;16:6589–97.

105. Montes A.F., Rivera F.V., Lago N.M. et al. Identification of the optimal patients for trifluridine/tipiracil (FTD/TPI) treatment in mCRC: A Spanish real-world analysis. J Clin Oncol 2020;38(Suppl 4):abstr.146.

106. Matsuda A., Yoshida Y., Kamiyama H. et al. The pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy and prognosis in metastatic colorectal cancer treated with the combination of TAS-102 and bevacizumab (TAS-CC3 Study). J Clin Oncol 2020;38(Suppl 40):abstr.224.

107. Argiles G., Yoshino T., Ohtsu A. et al. Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study. J Clin Oncol 2018;36(Suppl 4S):abstr.744.

108. Masuishi T., Moriwaki T., Fukuoka S. et al. Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. J Clin Oncol 2019;37(Suppl):abstr.3560.

109. Wu Y., Fan Y., Dong D.F. et al. Efficacy and safety of regorafenib as third-line therapy in metastatic colorectal cancer: An indirect meta-analysis. J Clin Oncol 2020;38(Suppl 4):abstr.119.

110. Patel A.K., Duh M.S., Barghout V. et al. Real-world treatment patterns among patients with colorectal cancer treated with Trifluridine/Tipiracil and Regorafenib. Clin Colorectal Cancer 2018;17(3):e531–9.

111. Chida K., Kotani D., Sawada K. et al. Survival impact on regorafenib (REG) and trifluridine/tipiracil hydrochloride (FTD/TPI) for patients with metastatic colorectal cancer: Single institutional experience. J Clin Oncol 2020;38(4 Suppl)43.

112. Kawakami T., Masuishi T., Kawamoto Y. et al. The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 2019;30(Suppl 5):v198–v252.

113. Masuishi T., Taniguchi H., Kawakami T. et al. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. ESMO Open 2019;4:e000584.

114. Zhang W., Suenaga M., Schirripa M. et al. Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. J Clin Oncol 2016;34(Suppl):abstr.3580.

115. Yoshino T., Yamazaki K., Shinozaki E. et al. Relationship between thymidine kinase 1 expression and Trifluridine/ Tipiracil therapy in refractory metastatic colorectal cancer: a pooled analysis of 2 randomized clinical trials. Clin Colorectal Cancer 2018;17(4):e719–e732.

116. Suenaga M., Schirripa M., Cao S. et al. Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. J Clin Oncol 2016;34(Suppl):abstr.3579.

117. Suenaga M., Mashima T., Kawata N. et al. Identification of biomarkers for TAS-102 efficacy in metastatic colorectal cancer patients based on preclinical analysis and clinical validation. J Clin Oncol 2018;36(Suppl 4S):abstr.669.

118. Tsunekuni K., Konno M., Asai A. et al. MicroRNA profiles involved in trifluridine resistance. Oncotarget 2017;8(32):53017–27.

119. Sueda T., Sakai D., Kudo T. et al. Efficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies. Anticancer Res 2016;36(8):4299–306.

120. Matsuoka K., Nakagawa F., Tanaka N. et al. Effective sequential combined chemotherapy with trifluridine/ tipiracil and regorafenib in human colorectal cancer cells. Int J Mol Sci 2018;19:2915.

121. Taieb J., Falcone A., Lonardi S. et al. Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study. Ann Oncol 2018;29(Suppl 8):viii150–204.


Для цитирования:


Федянин М.Ю. Трифлуридин / типирацил (FTD / TPi, TAs-102) в лечении больных метастатическим раком толстой кишки: от предклинических экспериментов до рутинной практики. Тазовая хирургия и онкология. 2020;10(3-4):11-26. https://doi.org/10.17650/2686-9594-2020-10-3-4-11-26

For citation:


Fedyanin M.Yu. Trifluridine / tipiracil (FTd / TPI, TAS-102) in the treatment of patients with metastatic colon cancer: from preclinical experiments to routine clinical practice. Pelvic Surgery and Oncology. 2020;10(3-4):11-26. (In Russ.) https://doi.org/10.17650/2686-9594-2020-10-3-4-11-26

Просмотров: 44


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2413-0583 (Print)
ISSN 2686-9594 (Online)